Rockland Immunochemicals and Emory U sign master reagent pact
GILBERTSVILLE, Pa.—Rockland Immunochemicals Inc. and Emory University last month announced a collaboration to develop novel antibodies and antibody-based tools for cancer, cell signaling and chromatin research. The partners will develop new antibody-based reagents capable of identifying targets for use on platform technologies currently used in research and clinical laboratories. Rockland supports the biopharma and diagnostic industries with antibodies and antibody-based tools for basic research, assay development and preclinical studies. The company develops new technologies for the production of antibodies for western blotting, immunohistochemistry (IHC), immunofluorescence microscopy, ELISA and FLOW cytometry.
"We have used the expertise at Rockland for many years to develop terrific antibody reagents for our basic science projects to understand how the immune system functions. This new collaboration/partnership will allow novel reagents to be developed for both basic science research and ultimately translational applications," says Dr. Jeremy M. Boss, professor and chair of microbiology and immunology at Emory.